← Eichor
Study identifier: NCT05908227 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants

Condition: Respiratory Distress Syndrome  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants150
Who can joinAll sexes, 23 Weeks to 31 Weeks
Healthy volunteersNo

About this study

Premature babies often need help breathing for a longer period of time. Traditionally, this is done with a breathing aid called NCPAP (nasal continuous positive airway pressure). This treatment is safe and effective, but it is very time-consuming and can sometimes have side effects. In the present research project, the investigators want to find out whether another type of breathing aid called NHF (nasal high flow therapy) is just as effective for stable premature babies. The investigators suspect that NHF is just as effective, but easier to use and more comfortable.

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Marie Bünte  ·  +41 31 632 19 23  ·  lisamarie.buente@insel.ch

André Kidszun, Prof. Dr. med.  ·  +41 31 632 14 01  ·  andre.kidszun@insel.ch

Always discuss trial participation with your own doctor first.

Locations (2)

University Medical Center of the Johannes Gutenberg-University MainzMainz, Rhineland-Palatinate, GermanyRecruiting
Department of Pediatrics, InselspitalBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05908227